Methazolamide Stats & Data
Pharmacology
DrugBankDescription
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Mechanism of Action
Methazolamide is a potent inhibitor of carbonic anhydrase. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
Pharmacodynamics
Methazolamide is topical carbonic anhydrase inhibitor. Methazolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not-considered an effective anticonvulsant. Methazolamide has a weak and transient diuretic effect, therefore use results in an increase in urinary volume, with excretion of sodium, potassium and chloride.
Absorption
Methazolamide is well absorbed from the gastrointestinal tract.
Toxicity
Electrolyte imbalance, development of an acidotic state, and central nervous system effects might be expected to occur in the case of an overdose.
Indication
For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma
Effect Profile
CuratedStrong anxiolysis and euphoria with moderate cognitive impairment, mild sedation